CD8A and neoplasm: Du and colleagues demonstrated that sitravatinib alters the immune landscape of tumors by reducing the number of tumor-associated immunosuppressive myeloid cells and increasing the number of CD4+ T cells and proliferating CD8+ T cells [130].